Amplia Therapeutics Limited
ATX.ASXHealth Care
Market Data
$0.140
+0.0%$69.3M
-100000.0x
$-0.020
0.00%
-0.4%
Latest Earnings
Preliminary Final Report and Annual Report YE 31 March 2026
29 May 2026
Amplia Therapeutics, a clinical-stage biotech focused on oncology, reported FY2026 results with revenues up 35% to $5.49M and net loss of $7.71M (17% increase). The company achieved significant clinical progress with mature ACCENT trial data showing narmafotinib in combination with chemotherapy delivering a 36% objective response rate and 11.1-month median overall survival, substantially outperforming historical benchmarks, while securing $27.5M in capital funding and achieving major manufacturing and regulatory milestones. Key points: ACCENT trial achieved 36% confirmed objective response rate vs. 23% historical benchmark for chemotherapy alone, representing substantial clinical improvement; Mature ACCENT data showed 11.1-month median overall survival vs. ~9 months for chemotherapy alone (approximately 2-month improvement) with 7.8% complete response rate (5/64 patients) – unprecedented in metastatic pancreatic cancer; Secured $27.5M in capital funding ($25M placement + $2.65M share purchase plan) and received $3.77M R&D tax rebate, strengthening financial position
Recent Announcements
Preliminary Final Report and Annual Report YE 31 March 2026
Amplia Therapeutics, a clinical-stage biotech focused on oncology, reported FY2026 results with revenues up 35% to $5.49M and net loss of $7.71M (17% increase). The company achieved significant clinical progress with mature ACCENT trial data showing narmafotinib in combination with chemotherapy delivering a 36% objective response rate and 11.1-month median overall survival, substantially outperforming historical benchmarks, while securing $27.5M in capital funding and achieving major manufacturing and regulatory milestones. Key points: ACCENT trial achieved 36% confirmed objective response rate vs. 23% historical benchmark for chemotherapy alone, representing substantial clinical improvement; Mature ACCENT data showed 11.1-month median overall survival vs. ~9 months for chemotherapy alone (approximately 2-month improvement) with 7.8% complete response rate (5/64 patients) – unprecedented in metastatic pancreatic cancer; Secured $27.5M in capital funding ($25M placement + $2.65M share purchase plan) and received $3.77M R&D tax rebate, strengthening financial position
Get real-time alerts for ATX
Receive AI-powered earnings summaries and instant notifications when Amplia Therapeutics Limited releases results.
Register Free